Rare diseases
Investigational molecules
Locations
Recruiting trials first
2 clinical trials in this condition
Safety Study of Tradipitant for Patients with Idiopathic or Diabetic Gastroparesis
BelgiumStudy on the Safety and Effectiveness of Naronapride for Adults with Moderate Idiopathic or Diabetic Gastroparesis
AustriaIn short
Diabetic gastroparesis is a complication that affects how quickly food moves through the stomach in people living with diabetes. When blood sugar levels remain high over time, nerve damage can occur, causing the stomach muscles to work more slowly or stop working properly. This leads to uncomfortable symptoms and makes managing diabetes even more challenging.
Treatment for diabetic gastroparesis focuses on helping people feel more comfortable, improving their ability to eat and absorb nutrients, and gaining better control over blood sugar levels. Because the stomach doesn't empty food as it should, managing this condition becomes a careful balance between controlling symptoms and preventing complications like malnutrition and dehydration.
The approach to treatment depends on how severe the symptoms are and how long someone has been dealing with the condition. Most people with diabetic gastroparesis have lived with diabetes for at least ten years and often have other complications related to the disease. This means that treatment plans need to consider not just the delayed stomach emptying, but also the broader picture of diabetes management and overall health.
There is currently no cure for diabetic gastroparesis, but the condition can be managed through a combination of approaches. Medical societies recommend starting with lifestyle changes, particularly modifications to diet and eating habits, alongside careful blood sugar control. When these measures aren't enough, doctors may prescribe medications that help the stomach muscles work better. For those who don't respond to standard treatments, there are also newer therapies being studied in clinical trials that show promise for the future.
The foundation of managing diabetic gastroparesis begins with controlling blood sugar levels. Hyperglycemia, which means having blood glucose levels higher than 200 mg/dL, can make stomach emptying even slower. This creates a difficult cycle where delayed stomach emptying makes blood sugar harder to control, and high blood sugar makes gastroparesis symptoms worse. Healthcare providers work closely with patients to adjust insulin timing and dosing, sometimes recommending taking insulin after meals instead of before, or checking blood glucose levels more frequently after eating.
Diet modifications form the cornerstone of treatment and often provide the most relief. Instead of eating three large meals a day, people with diabetic gastroparesis are advised to eat five to seven small meals throughout the day. Foods should be low in fat and fiber, as both of these slow down stomach emptying. Fat naturally takes longer to digest, and fiber can remain in the stomach, potentially forming a hardened mass called a bezoar. Patients are encouraged to eat soft, well-cooked foods, chew thoroughly, and avoid carbonated beverages and alcohol. Staying hydrated is essential, with recommendations to drink water, low-fat broths, or sports drinks that provide electrolytes.
When dietary changes and blood sugar control aren't enough, medications called prokinetic agents can help. These drugs stimulate the stomach muscles to move food through more effectively. Metoclopramide is one of the most commonly prescribed prokinetics and works by enhancing the muscle contractions in the stomach wall. Studies show that between 25% and 68% of symptoms can be controlled with prokinetic medications. However, metoclopramide can cause side effects, including fatigue and movement disorders, especially with long-term use, so doctors monitor patients carefully.
Domperidone is another prokinetic agent that works similarly to metoclopramide but with fewer neurological side effects. In some countries, it's preferred for longer-term treatment. Erythromycin, which is actually an antibiotic, has prokinetic effects and can help stimulate stomach emptying. It's sometimes used when other medications haven't worked, though its effectiveness may decrease over time. Doctors may also prescribe medications specifically to control nausea and vomiting, such as antiemetics, which help patients feel more comfortable and able to eat.
For severe cases that don't respond to medications, gastric electrical stimulation may be considered. This involves surgically implanting a device that sends mild electrical pulses to the stomach muscles, similar to how a pacemaker works for the heart. Open-label studies have shown that this therapy can improve symptoms, reduce the number of hospitalizations, decrease the need for feeding tubes or nutritional support, and improve quality of life. The procedure requires surgery to place the device, and patients need to have regular follow-ups to ensure it's working properly.
The duration of treatment varies greatly from person to person. Some individuals find that with careful management of blood sugar and diet, their symptoms remain stable and manageable. Others may need ongoing medication therapy or more intensive interventions. The symptoms of gastroparesis typically persist once they begin and often remain stable over 12 to 25 years, even when blood glucose levels are well controlled. This underscores the importance of finding a sustainable treatment approach that fits into each person's lifestyle.
Beyond standard treatments, researchers are actively investigating new approaches to help people with diabetic gastroparesis. Clinical trials are exploring innovative molecules and therapies that target different aspects of the condition, from the underlying nerve damage to the way the stomach muscles respond to signals from the brain.
While specific experimental drugs and their code names are still being evaluated in research settings, the general approach in many trials focuses on understanding the underlying mechanisms that cause gastroparesis. Scientists are studying how neuronal nitric oxide synthase (nNOS) plays a role in stomach muscle function. When this enzyme is lost due to chronic high blood sugar, it may contribute to delayed gastric emptying. Some research is exploring whether therapies that restore or mimic nNOS function could help improve stomach motility.
Another area of investigation involves the interstitial cells of Cajal, which act as pacemaker cells in the stomach. These specialized cells help coordinate muscle contractions that move food through the digestive system. Diabetes can damage these cells, and researchers are looking into ways to protect them or stimulate their growth. This represents a potential future treatment pathway, though such therapies are still in early research phases.
Some clinical trials are examining whether therapies that target the vagus nerve might offer benefits. The vagus nerve controls stomach function, and in diabetic gastroparesis, this nerve is often damaged. Researchers are exploring various approaches, from medications that might protect the nerve to devices that stimulate it in specific ways. These studies are generally in Phase I or Phase II, meaning they are evaluating safety and beginning to look at effectiveness in small groups of patients.
The locations of clinical trials for gastroparesis span multiple countries, with significant research activity in the United States, Europe, and other regions. Patients interested in participating typically need to meet specific criteria, such as having had diabetes for a certain number of years, experiencing symptoms of a particular severity, and having tried standard treatments without adequate relief. Clinical trial participation offers access to cutting-edge therapies while also contributing to the broader understanding of the condition.
It's important to understand that clinical trials progress through several phases. Phase I trials primarily evaluate safety and determine the appropriate dose of a new treatment in a small group of people. Phase II trials expand the study to more participants to assess whether the treatment actually improves symptoms and to monitor for side effects. Phase III trials involve larger groups and often compare the new treatment directly with current standard therapies to see if it offers additional benefits.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
